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Abstract
Somatic forward genetic screens have the power to interrogate thousands of genes in a single animal. Retroviral and
transposon mutagenesis systems in mice have been designed and deployed in somatic tissues for surveying hematopoietic
and solid tumor formation. In the context of cancer, the ability to visually mark mutant cells would present tremendous
advantages for identifying tumor formation, monitoring tumor growth over time, and tracking tumor infiltrations and
metastases into wild-type tissues. Furthermore, locating mutant clones is a prerequisite for screening and analyzing most
other somatic phenotypes. For this purpose, we developed a system using the piggyBac (PB) transposon for somatic
mutagenesis with an activated reporter and tracker, called PB-SMART. The PB-SMART mouse genetic screening system can
simultaneously induce somatic mutations and mark mutated cells using bioluminescence or fluorescence. The marking of
mutant cells enable analyses that are not possible with current somatic mutagenesis systems, such as tracking cell
proliferation and tumor growth, detecting tumor cell infiltrations, and reporting tissue mutagenesis levels by a simple ex
vivo visual readout. We demonstrate that PB-SMART is highly mutagenic, capable of tumor induction with low copy
transposons, which facilitates the mapping and identification of causative insertions. We further integrated a conditional
transposase with the PB-SMART system, permitting tissue-specific mutagenesis with a single cross to any available Cre line.
Targeting the germline, the system could also be used to conduct F1 screens. With these features, PB-SMART provides an
integrated platform for individual investigators to harness the power of somatic mutagenesis and phenotypic screens to
decipher the genetic basis of mammalian biology and disease.
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Introduction
Transposon insertional mutagenesis (TIM) is a powerful tool for
inducing and identifying mutations of interest and has been utilized
with great effect in many organisms, from the bacterium to the fruit
fly Drosophila melanogaster [1,2]. The Sleeping Beauty (SB) and piggyBac
(PB)DNAtransposonshavebeenrecentlydevelopedforTIMinmice
and human cells [3,4,5]. As one of the first applications of TIM in
mammals, SB and PB have been used to identify tumor-promoting
genes for multiple tumor types in mice [6–13]. In addition, SB
transposase has been activated by tissue-specific Cre expression for
the successful induction of colorectal adenocarcinoma, hepatocellular
carcinoma, and B-cell lymphoma [10,11,13]. The successful
induction of tumors by SB and PB indicates that a more versatile
somatic TIM system can be established for broad application.
Somatic genetic screening requires animal breeding and
significant lengths of time for manifestation of phenotypes such
as tumorigenesis. Thus, it represents substantial investments of cost
and time for mammals. Although tumor induction by SB TIM has
been successful in multiple tissues, tumors in a number of other
tissues have yet to be found despite employing the same mutator
transposons and whole-body mutagenesis approach. This high-
lights the importance of determining the feasibility of TIM for the
tissue of interest. Although one could molecularly determine
mutagenesis efficiency before the manifestation of phenotype, it is
not desirable to sacrifice valuable experimental animals during the
course of the screen. It would be ideal to have a method to easily
determine whether TIM in a targeted tissue is feasible at the outset
of the screen without sacrificing animals.
Moreover, while tumors are readily identifiable, pre-tumorous
lesions and metastatic clones are difficult to locate without visible
markers. Furthermore, marking mutant clones is a prerequisite for
screening and analyzing most other somatic phenotypes. Visibly
marking mutant somatic clones has been employed in Drosophila,
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in analyzing a variety of processes including cell proliferation and
migration, neurobiology and other clonal behaviors in vivo [14–17].
Thus, a somatic TIM system that can be used to screen for
phenotypes other than tumor formation must incorporate the
ability to track mutagenized cells.
Somatic mutagenesis screening has the genetic power to
conduct genome-wide interrogation with a small number of
animals. A highly efficient somatic TIM system would allow
genetic screens to be performed with low copy numbers of
transposon, thus allowing easy identification of causative muta-
tions. Finally, it is optimal that the genetic elements for the features
described above to be integrated such that somatic TIM can be
conducted with one generation of breeding.
The PB transposon system has been shown to be highly efficient
in mammals [3]. Its distinct properties of precise excision [3,18],
large payload capacity [3], and genome-wide insertion tendency
[3,12] offer a unique opportunity to create a somatic TIM system
with broad utility. Here, we describe a method for PB somatic
mutagenesis with an activated reporter and tracker in mice (PB-
SMART). In this system, mobilization of the PB mutator
transposon activates luciferase for the ex vivo reporting of
mutagenesis activity levels, providing feasibility assessment at the
outset of a genetic screen. The activation of luciferase or a red
fluorescent protein also featured in this system further enables
visual tracking of mutated cells. The integration of the mutagenesis
reporter, mutant cell tracker, and mutagenic transposon into a
single transgene greatly simplifies genetic breeding. Further
incorporation of Cre-inducible PB transposase (PBase) transgenes
allows tissue-specific somatic TIM screens to be conducted with
one genetic cross. Finally, we show that PB-SMART can induce
somatic phenotypes, track clonal behavior of mutated cells, and
allow easy identification of causative insertions. Thus, PB-SMART
provides a powerful means for individual investigators to decipher
the genetic basis of mammalian biology and disease.
Results
Generating a PB mutator transposon for multiple
genomic contexts
PB has previously been found to integrate at high frequency
near or within genes [3]. To efficiently induce somatic mutations,
we generated a PB mutator transposon (Figure 1A, PB[mut])t o
induce ectopic gene expression in multiple genomic contexts. The
CMV early enhancer/chicken b-actin promoter was cloned
between the PB transposon arms to induce overexpression of
genes downstream of a transposon insertion site. A myc epitope in
all three reading frames and a splice donor were placed after the
Actin promoter such that transcription and translation initiation
can incorporate the myc tag sequence prior to splicing into
endogenous exons. The CMV enhancer can also act as a
bidirectional enhancer to upregulate genes. Additionally, in the
event that PB[mut] inserts into an intron, an N-terminally
truncated product can be ectopically induced. Insertions into
introns can also produce C-terminally truncated gene products
initiated by the endogenous promoter. A splice acceptor followed
by a sequence with stop codons in all three frames and a poly(A)
signal was added for this purpose. Expression of truncated genes
may produce dominant active and dominant negative proteins.
Thus, by design, the PB[mut] transposon can induce the ectopic
expression of full-length or truncated endogenous genes in many
different genomic contexts (Figure 1A). Indeed, PB[mut] can
induce ectopic full-length and truncated gene expression in PB-
SMART screens (see below).
PB somatic mutagenesis with an activated luciferase
reporter
In order to develop a somatic mutagenesis system that can
induce mutations while simultaneously and non-invasively (ex vivo)
reporting mutagenesis levels in tissues, we engineered a strategy to
bioluminescently mark cells in which transposon mobilization has
occurred. We took advantage of the highly sensitive luciferase
reporter gene [19] by inserting PB[mut] at a TTAA tetranucleotide
target site within the coding sequence (Figure 1A, Luc-PB[mut]),
thereby preventing luciferase expression from an upstream Actin
promoter. During mutagenesis, active PB transposase (PBase)
catalyzes the precise excision of the PB mutator transposon and a
full-length luciferase product is reconstituted (Figure 1A). Five Luc-
PB[mut] transgenic lines were established and their ability to report
PBase activity was tested by crossing to our previously described
Act-PBase line [3]. The Luc-PB[mut]7 line was identified as the most
robust reporter for PB mutagenesis activity that can be easily
assayed by ex vivo imaging (Figure 1B). Luc-PB[mut]7 behaves as a
faithful reporter for PBase activity, since it does not produce any
luciferase signal in mice lacking PBase (Figure 1B).
To examine whether Luc-PB[mut]7 can differentiate between
varying levels of PBase activity, we generated transgenic mice
expressing a PBase-Estrogen Receptor fusion transgene (Act-
PBaseER). In the inactive state, the PBaseER protein is sequestered
in the cytoplasm. Stimulation with tamoxifen shuttles PBaseER to
the nucleus and activates its ability to drive PB transposition
(Figure S1). In vivo, luciferase signal was not observed in newly
weaned, untreated Luc-PB[mut]7;Act-PBaseER transgenic mice.
However, transgenic Act-PBaseER can mobilize PB upon tamox-
ifen administration (Figure 1C) and luciferase signal can be
detected one week after treatment, providing a tool for conditional
PB TIM. Quantitative PCR measuring PB[mut] excision revealed
that PBaseER activity levels were significantly lower than those of
Act-PBase (Figure 1C). These results were corroborated by the
luciferase mutagenesis reporter signal from ex vivo imaging
(Figure 1C). Furthermore, we sometimes observed leaky luciferase
signal in older, untreated mice housed together with tamoxifen-
treated mice (data not shown). This signal, however, is at least an
order of magnitude lower than signal from treated mice as
measured by ex vivo imaging (data not shown). The ability to
differentiate between differing levels of luciferase signal indicates
that Luc-PB[mut]7 is a sensitive reporter for PBase activity.
By real-time PCR analysis, the Luc-PB[mut]7 transgenic line was
found to contain seven copies of the mutagenic transposon. When
crossed to Act-PBase mice, the number of live-born double
transgenic pups was 93% of the expected number (n.100). Since
mutagenesis in Luc-PB[mut]7;Act-PBase mice was observed in all
tissues as reported by luciferase, we addressed whether this low
copy line is sufficient to induce different phenotypes when
mutagenesis is targeted in all tissues or specific organs. We found
Luc-PB[mut]7 can induce tumor formation as well as other
phenotypes including cellular features (e.g., cell infiltration and
clonal expansion) and morphological defects (e.g., alopecia) (also
see below).
We found that body-wide PB-SMART can induce tumor
formation in non-sensitized backgrounds. We observed that Luc-
PB[mut]7;Act-PBase and Luc-PB[mut]7;Act-PBase;Cre mice developed
tumors while conducting sensitized screens. Nine out of 32 of these
Luc-PB[mut]7;Act-PBase(Cre) mice developed tumors within 50
weeks while only one out of seventeen Act-PBase(Cre) and zero
out of 32 Luc-PB[mut](Cre) controls developed a tumor (Figure 1D).
We have collected additional tumors from cohorts that have not
reached 50 weeks and other non-sensitized cohorts containing
floxed latent alleles of Pten loss or Braf activation [20,21]. Across
PB-SMART for Genetic Screens in Mice
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kidney and pancreatic tumors, lung adenocarcinoma, hepatocel-
lular carcinomas, soft tissue sarcomas such as angiosarcoma and
small round blue cell (SRBC) tumors, and skin tumors such as
squamous cell carcinoma, sebaceous cancer, and melanoma.
These results confirm that our low copy PB-SMART system can
efficiently induce tumor-promoting mutations in a wide variety of
tissues.
We also found that the low copy mutagenic transposon in the
PB-SMART system allows for easy identification of potential
causative insertional mutations. Transposon insertions from
tumors were mapped by linker-mediated PCR (LM-PCR). On
Figure 1. Simultaneously inducing mutations and reporting mutagenesis activity levels with a PB transposon system. (A) The Actin
promoter (black pointed box) and myc-splice donor sequence (blue box) are engineered in the PB[mut] transposon to ectopically express
downstream genes or partial transcripts. A splice acceptor and transcriptional termination sequences (pink box) truncate transcripts initiating
upstream of the transposon insertion site. PB[mut] is inserted within an internal TTAA sequence of the luciferase gene to create Luc-PB[mut].
Transposase excises PB[mut] from the luciferase gene, restoring the luciferase expression and thus labeling cells. (B)B yex vivo luciferase imaging, PB




(C) Quantitative PCR analysis of transposon excision in the Luc-PB[mut]7 line demonstrates a 30-fold increase in transposition activity between Act-
PBase and Act-PBaseER (top). The difference in mutagenesis activity levels driven by Act-PBaseER (middle) and Act-PBase lines (right) can be
differentiated by the luciferase PB reporter. Units, photons?s
21?cm
22?sr
21.( D) Tumor-free survival curves over the span of 50 weeks show that Luc-
PB[mut]7;Act-PBase(Cre) mice succumb to tumors while Luc-PB[mut]7(Cre) and Act-PBase(Cre) littermates remain relatively tumor-free.
doi:10.1371/journal.pone.0026650.g001
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mapped. Notably, greater than 64% of all insertions were
recovered in introns, exons, or within ten kilobase pairs (kb) of
either known or predicted genes (Table 1). Given the propensity of
Luc-PB[mut] for inserting into or near genes in these tumors, we
analyzed whether the mutator transposon was oriented along or
opposite the coding direction of inserted genes. Because our
mutator transposon is designed to overexpress full-length genes or
truncated genes, we expected that in tumors, insertions oriented
along the coding direction of nearby or affected genes would be
enriched versus insertional orientation by random chance. Indeed,
over 64% of intron insertions were oriented along the coding
direction of the affected genes, and almost 60% of insertions
within 10 kb upstream of genes were oriented toward the coding
direction of the nearby genes (Table 2). Meanwhile, insertions
within 10 kb downstream of nearby genes displayed less bias for
mutator orientation (Table 2). These data imply that the PB
mutator transposon is indeed upregulating genes important for
tumorigenesis.
In five kidney tumors, we identified common insertions in Mitf.
The mutator transposons in all five tumors were inserted in the
coding direction, upstream of the translational start of the M-
isoform, suggesting overexpression of Mitf in these tumors
(Figure 2A). Indeed, quantitative PCR revealed that Mitf was
upregulated in these kidney tumors as compared to two wild-type
kidney samples (Figure 2B). Histopathology of the kidney tumors
revealed an expansion of nests of pleomorphic spindle and
epithelioid cells suggestive of carcinoma (Figure 2C).
Notably, two other members of the MiT family of basic-helix-
loop-helix/leucine zipper transcription factors, TFE3 and TFEB,
have been recurrently affected by translocations that result in the
upregulation of these transcription factors in human pediatric
renal cell carcinoma [22–26]. Since TFE3, TFEB, and MITF are
highly homologous and bind to the same DNA consensus
sequence, it is likely that they can substitute for each other as
oncogenes [27]. Together, these data suggest that MITF
upregulation is an important driver for kidney tumor formation.
We alsoidentified Gli2, a downstreameffectoroftheHedgehog(Hh)
signaling pathway [28], as a common insertion site in SRBC
tumors. We mapped coding-direction insertions in intron 7 or
intron 8 from 11 tumors displaying SRBC morphology (Figures 2D
and 2E). Gli2 contains a repressor domain in the amino-terminus,
and expression of the C-terminal portion of Gli2 has previously
been shown to result in the constitutive transcriptional activation of
downstream target genes [29,30]. In these sarcomas, it is likely that
the Gli2 insertions lead to the expression of constitutive transcrip-
tional activator forms of Gli2 that drive tumor formation. In fact,
constitutive Hedgehog signaling in Gorlin’s syndrome due to
mutation in PTCH leads to an increased propensity to develop an
SRBC tumor,rhabdomyosarcoma[31,32].Furthermore,activation
of Gli1 (a Gli2 transcriptional target) seems to be a major
downstream effector of the EWS-FLI1 oncoprotein which drives
anotherSRBC tumor,Ewing Sarcoma [33,34].Togetherthesedata
strongly support the notionthat constitutive Hedgehog signalingis a
critical driver in SRBC tumor formation, with overexpression of
truncated Gli2 being one mechanism. Thus, the identification of
cancer genes with known human relevance validates the utility of
our low-copy mutator for uncovering disease genes.
PB somatic mutagenesis with an activated RFP cell
tracker
In somatic mutagenesis, the ability to track mutated cells via the
same transgenic line used to induce mutations opens up many
experimental possibilities. We thus added new elements in our PB
mutator transposon to label the mutant cells. The RFP coding
sequence and an internal ribosome entry site (IRES) were inserted
between the Actin promoter and myc-SD, which contains start
codons in all three reading frames followed by a splice donor, of
PB[mut] (Figure 3A, PB[mut-RFP]). Following insertions into introns
or 59 regulatory regions, production of bicistronic pre-mRNA
containing RFP, IRES, the engineered myc-SD exon, and
downstream endogenous intronand exon sequencescanbe initiated
by the Actin promoter. After splicing of the myc-SD exon to
downstream endogenous splice acceptors, the bicistronic transcripts
enables the expression of RFP and the ectopic expression of
endogenous proteins (Figure 3A). When we tested this mutator in
cultured cells, the activated RFP marker was co-expressed in cells
that ectopically expressed downstream endogenous proteins that
incorporated the engineered myc-SD exon (Figure 3B). In order to
ensure that PB[mut-RFP] does not express RFP from a transgenic
concatamer, a concatamer silencer (CS) was inserted outside of the
transposon (Figure 3A). The CS contains a splice acceptor followed
by stop codons in all three reading frames to terminate transcripts
initiated by the Actin promoter from transgene concatamers. To
prevent alternative splicing–mediated exclusion of the CS splice
acceptor, a sequence forming a pre-tRNA-like (DAC) structure was
cloned after the stop codons. This substrate is efficiently recognized
and cleaved by RNase P ensuring that pre-mRNA which contain
the CS do not form mature transcripts [35].
We generated seven transgenic lines varying in transposon copy
number from two copies to 200 copies (Figure 3C) and found that
none were RFP-positive, indicating that the CS successfully
prevents undesired RFP production. When the two highest copy
lines were crossed to the Act-PBase line, live-born double transgenic
progeny were rarely observed (Figure 3D), suggesting that the
mutagenic transposons can be mobilized by Act-PBase during
embryonic development and can induce significant deleterious
effects and embryonic lethality. The mobilization of the low copy
Table 1. Insertional frequency in tumors induced by
Luc-PB[mut]7 and PB[mut-RFP]7.
PB insertions in % of total hits





59 regulatory sequences (#10 kb) 9.9
39 regulatory sequences (#10 kb) 4.8
doi:10.1371/journal.pone.0026650.t001
Table 2. Mutator orientation in tumors induced by
Luc-PB[mut]7 and PB[mut-RFP]7.
PB insertions in % of hits in coding direction
Exons 60.0
Introns 64.1
59 regulatory sequences (#10 kb) 59.3
39 regulatory sequences (#10 kb) 53.8
doi:10.1371/journal.pone.0026650.t002
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Importantly, mutagenesis using either of the two-copy or the
seven-copy PB[mut-RFP] lines crossed to Act-PBase mice resulted in
the appearance of RFP-positive patches (Figure 3F) and triggered
tumorigenesis (Figure 3G), validating these three low copy PB[mut-
RFP] lines for somatic mutagenesis with an activated cell tracker.
Tissue-specific PB somatic mutagenesis screening with
an activated reporter and tracker (PB-SMART screen)
We have shown that the collective luciferase signal in tissues
generated by Luc-PB[mut]7 can act as a robust reporter of
mutagenesis activity. Since Luc-PB[mut]7 is also a mutator, the
luciferase signal could also be used to mark the mutant cells. Given
that Luc-PB[mut]7 is a low copy line and not every cell in a tissue
will be luciferase positive, we reasoned that clones or patches of
mutant cells will have elevated signals and could be detected
through ex vivo imaging. In this sense, the luciferase reporter also
behaves as a tracker for mutant cells. By monitoring ex vivo
luciferase signal, we identified clonal patches in the skin and
tracked the appearance of melanomas in Luc-PB[mut]7;Act-
PBase;Braf
CA;Tyr-CreER mice (Figures 4A and 6A; also see below).
In addition, the luciferase signal enabled the identification of
tumor cell infiltration into distant organs of a Luc-PB[mut]7;Act-
PBase;Pten
+/- mouse that developed lymphoma (Figure 4B). The
enlarged thymus and lymph nodes were strongly luciferase-positive
due to the dense clustering of cells that activated the luciferase
reporter (Figure 4B). Strong signal was also seen emanating from a
distinct portion of the liver (Figure 4B). Histology revealed that the
luminescent spot was indeed infiltration of lymphocytes
(Figure 4C), and we mapped identical transposon insertions from
the liver infiltration and other tumor sites, indicating that the cells
originated from the same clone. Thus, the Luc-PB[mut]7 line is a
mutant clone tracker for monitoring clonal expansion, tumor
formation, and infiltrations of cells into foreign tissues.
We further expanded the PB-SMART system for tissue-specific
genetic screens. To allow the system to be readily adopted for
screens in many types of tissues and cells, we generated transgenic
mice in which PBase or PBaseER can be activated by tissue-specific
Cre by inserting a Stop-pA sequence flanked by loxP sites between
the Actin promoter and the transposase coding sequence
(Figure 5A, LSL-PBase, LSL-PBaseER). When these double
transgenics were crossed into lines expressing Cre in the kidney
and genitourinary tract or the skin epithelium [36,37], correct
targeting of mutagenesis to these tissues was confirmed by the
luciferase reporter (Figures 5B and 5C).
To ask whether Luc-PB[mut]7 can be used to track mutation-
driven expansion of cells, we utilized the Tyr-CreER line, which
expresses CreER specifically in melanocytes [38], one of the least
densely clustered cell types in the body. Tyr-CreER has been used
to conditionally activate Braf
V600E, thereby promoting melanocyte
proliferation [20,21]. We generated Luc-PB[mut]7;LSL-PBase;
Braf
CA;Tyr-CreER quadruple transgenic mice and assayed whether
luciferase can track mutation-driven expansion of cells ex vivo. After
administering tamoxifen, we were able to detect luciferase signal in
melanocytes in the ears, tail, and dorsal trunk and also track the
expansion of the positive cells over time (Figure 5D).
To further illustrate that Luc-PB[mut]7 can be used to track
clonal expansion in specific cell types, we targeted the PB-SMART
system to the mouse skin. We generated Luc-PB[mut]7;LSL-
PBase;K14-Cre mice which express Cre specifically in the basal
keratinocytes of the epidermis. This compartment contains the
stem and progenitor cells that give rise to the hair follicle,
sebaceous gland, and interfollicular epidermis [39]. We reasoned
that if a keratinocyte stem or progenitor cell were to be targeted by
PB-SMART, over time an entire clonal unit would become
luciferase positive. Indeed, the appearance of distinct luciferase
clusters could be detected in these mice (Figure 6A).
Skin-specific PB-SMART resulted in tumor development as
well as other morphological phenotypes. For example, we
observed hair loss on dorsal skin, resulting from PB mutagenesis
and marked by luciferase signal (Figure 6B). Keratin staining of
frozen sections revealed a striking epidermal thickening in the
affected region (Figures 6C and 6D). We mapped a transposon
insertion upstream of Myc in the affected skin (Figure 6E). This is
consistent with previous reports that in K14-c-Myc transgenic mice,
Figure 2. Identification of driver oncogenes in solid tumors
from Luc-PB[mut]7;Act-PBase mice. (A) Insertions (wide arrows)
upstream of the M-isoform of Mitf were mapped from five kidney
tumors. (B) Quantitative PCR reveals that Mitf transcripts are upregulated
in all five kidney tumors (KT1, KT2, KT3, KT4, and KT5) compared to two
wild-type kidneys (wt-K). (C) Kidney tumors possessed similarhistological
profiles, featuring packets of spindle-shaped epitheliod cells, indicating
carcinoma (scale bar, 50 mm). (D) Histological analysis shows SRBC
morphology(scalebar,100 mm).(E)Insertions (widearrows)inintron7or
8o fGli2 were mapped from eleven SRBC tumors.
doi:10.1371/journal.pone.0026650.g002
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loss, hyperproliferation, and thickening of the interfollicular
epidermis [40,41].
We further analyzed skin tumors that were induced and labeled
by skin-specific PB-SMART. We were able to observe tumors in
Luc-PB[mut]7;LSL-PBase;K14-Cre mice starting at four months of
age. Using the ex vivo reporter system, we can detect regions of
luciferase activity prior to tumor formation, that correspond to the
later development of tumors (Figure 6F). In four of these tumors,
we identified transposon insertions in Gli2 (Figure 6G). Quanti-
tative PCR confirmed that Gli2 mRNA levels were increased in
these tumors as compared to wild type skin (Figure 6H).
Figure 3. Simultaneously inducing mutations and tracking mutated cells with a PB transposon system. (A) PB[mut-RFP] couples RFP
expression with ectopic expression of a downstream gene or partial gene transcript via the IRES (brown box). CS (purple box) prevents unwanted RFP
expression from transgene concatamers. (B) PB[mut-RFP] mobilization in HEK 293 cells induces RFP-positive clones that colocalize with myc-tagged
proteins ectopically expressed by the mutator transposon. (C) Transgenic lines carrying two to 200 copies of PB[mut-RFP] were generated.
(D) Significant PB transposition-induced embryonic lethality was observed when high-copy lines were crossed to Act-PBase.( E) Low-copy PB[mut-RFP]
lines crossed to Act-PBase mobilized the mutator transposon as determined by PCR with primers directed against sequences flanking the transposon.
A 212-bp excision product was specifically detected in double transgenics but not in single transgenic littermates. A 700-bp unexcised product was
observed in all PB[mut-RFP] mice. (F) Shown here in the dorsal skin of a PB[mut-RFP]2a;Act-PBase mouse, RFP-positive foci can be detected ex vivo
over background signal. Units, photons?s
21?sr
21?ı `M
21.( G) RFP-marked tumor formation (arrowhead) can be visualized ex vivo as seen in the upper
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in basal cell carcinoma (BCC) [42], which arises from stem cells in
the epidermis and hair follicle [43,44]. Furthermore, histopathol-
ogy of the skin tumors revealed palisading basaloid cells forming
tumor nests and retraction of the stroma from the tumor islands in
formalin-fixed sections similar to human BCC (Figure 6I).
Together, these data show that the PB-SMART system can be
deployed to conduct tissue-specific genetic screens and identify
causative mutations relevant to human disease.
Discussion
In the data presented, we have taken advantage of the PB
transposon’s properties to create a somatic mutagenesis system,
PB-SMART, to simultaneously mutate and mark cells for
conducting tissue-specific genetic screens in mice. In somatic
screens for cancer genes, PB-SMART offers advantages over
other TIM systems. Our system allows one to detect tumors
before their morphological manifestation and to monitor tumor
growth and dissemination ex vivo. Importantly, it allows one to
detect tumor formation ex vivo such that only tumor-positive
animals will be sacrificed in a screen. This is particularly critical
for screens of internal cancers as previous screens required
sacrificing large numbers of experimental animals at arbitrary
time points to search for tumors. The visible cell markers also
enable mutant clones in tissues to be readily identified and
continuously monitored over time. This is essential for the
detection of phenotypes other than tumors and provides many
experimental advantages for visualizing proliferation defects,
tracking cell migration, tracing cell lineages, and analyzing other
clonal behavior in vivo. As proof-of-principle examples, we
demonstrated that the system can be used to identify phenotypes
in PB mutant clones, detect cell infiltration, and track the
expansion of rare cell populations. In addition to these examples,
the luciferase and RFP mutator lines can be utilized in other ways
to confer specific experimental advantages according to the
biological process to be surveyed. For example, luciferase is
highly useful for detection and tracking of solid tumors
originating from deep tissues. On the other hand, RFP enables
detection and isolation of cells via fluorescence-activated cell
sorting which would be particularly useful for capturing
disseminated tumor cells in the bloodstream. As an additional
resource to facilitate use by the research community, we will
provide further detailed characterization of these and other
recently developed PB-SMART lines on our lab website (http://
info.med.yale.edu/genetics/xu).
The luciferase reporter integrated into the PB-SMART system
also allows mutagenesis efficiency to be visually assessed at the
onset of a genetic screen without sacrificing animals. Furthermore,
we have found that luciferase signal activated by PB mutagenesis is
highly indicative for the successful outcome of a mutagenesis
screen, providing a valuable predictive tool. Genetic screens in
mice are a significant investment. Since phenotypes in many
screens take significant time to manifest, it is a tremendous
advantage to have a predictive indicator at the beginning of the
experiments.
PB-SMART is also a highly efficient mutagenesis system.
Utilizing PB’s large payload capacity, we engineered elements in
PB to ectopically express genes or parts of genes and to terminate
transcripts upon insertion in many genomic contexts, thereby
creating highly mutagenic transposons. Together with PB’s high
transposition efficiency and genome-wide distribution, PB-
SMART is able to induce somatic phenotypes with low copy
(seven or fewer) transposons. The efficiency of the system is
highlighted by the fact that a broad spectrum of tumors is
induced with only seven copies of transposon. Importantly, low
transposon copy numbers allow for more straightforward
identification of causative insertions because there are fewer
bystander insertions. We found that over 64% of insertions in
tumors are mapped in introns, exons, or within 10 kb of genes.
This is a remarkably high gene insertional frequency indicative
that there is a selective advantage for PB gene insertions in
tumors. In two tumor types that have not previously been found
in somatic mutagenesis screens, we used common insertion site
analysis to identify Mitf as a driver in kidney tumor formation
and truncated Gli2 as a driver of SRBC tumors. Thus, PB-
SMART is a powerful tool to identify mutations relevant to
human disease.
For the creation of a tissue-specific mutagenesis system that can
be readily used by the research community for a variety of tissue
and cell types, we generated conditional transposase transgenic
lines that can be activated by Cre (LSL-PBase and LSL-PBaseER).
We showed that mutagenesis can be targeted specifically to the
skin or internal organs by crossing to tissue-specific Cre lines.
Temporal control of tissue-specific mutagenesis can also be
achieved by using LSL-PBaseER or by crossing to available CreER
lines, as we demonstrated in melanocytes with Tyr-CreER. Given
that specific Cre or CreER lines have been generated for almost
every mouse tissue being studied, our system will make it possible
to target any tissue for genetic screens. The combination of
conditional transposase lines and low copy PB mutator lines could
be used to target the germline for the generation of stable and
heritable mutations for traditional screens. More importantly,
mutations targeted at the germline could also be used to conduct
Figure 4. Tracking tumor formation and infiltration with Luc-
PB[mut]7. (A) Luciferase signal labels a melanoma in this Luc-
PB[mut]7;Act-PBase;Braf
V600E;Tyr-CreER mouse (white arrowheads). The
left panel shows a light image while the right panel overlays the
luciferase signal. (B) Luciferase signal enabled the identification of
tumor cell infiltration into distant organs of a Luc-PB[mut]7;Act-
PBase;Pten
+/- mouse that developed lymphoma. The enlarged thymus
(Thy) and lymph nodes (LN) were strongly luciferase-positive. Strong
signal was also seen emanating from a distinct portion of the liver (Liv,
white dashed line). (C) H&E staining of liver from the luciferase-positive
region reveals extensive lymphocyte infiltration (scale bar, 200 mm).
doi:10.1371/journal.pone.0026650.g004
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including embryonic and adult defects.
In summary, the ability to induce somatic mutations, report
mutagenesis levels, and track mutated cells permits many types of
applications and analyses that are not possible with current TIM
systems. Because induction and labeling of mutant cells are
simultaneously achieved by the same mutator transposon, the
design not only links the two events, but also simplifies genetics by
minimizing the number of transgenes involved. Furthermore, PB-
SMART also integrates the conditional transposase, which enables
TIM screens to be conducted for any tissue in the mouse by a
single genetic cross to a tissue-specific Cre line. The ability to
screen thousands of clones in a single animal in only one
generation makes it possible to achieve genome-wide interrogation
with a small number of animals in a short period of time. The
development of PB-SMART thus empowers individual investiga-




All experiments were approved by and conducted in compli-
ance with the Yale Animal Resources Center and the Institutional
Animal Care and Use Committee under protocol number 2008-
10230.
Plasmid construction
The Luc-PB[mut]7 and PB[mut-RFP] transposons were generated
from elements in the plasmids PB[Act-RFP] [3], pIRES (Clontech),
pBS302 (Life Technologies), pDAC [35], and pGL3 (Promega).
Myc-SD was PCR amplified from an oligonucleotide containing
ATG transcriptional initiation codons, myc epitope sequences in
all three reading frames, and a splice donor sequence. CS and part
of SA-stop-pA were PCR amplified from an oligonucleotide
containing a splice acceptor and stop codons in all three reading
frames (sequences available upon request). For PB[mut-RFP], loxP
sites were included to flank the mutagenic Act-RFP-IRES-myc-SD
cassette. All elements were constructed on a pBlueScript II SK+
(Stratagene) backbone before cloning between PBL and PBR
transposon arms to yield the final plasmid. For Luc-PB[mut],
luciferase from pGL3 was introduced outside PBL and PBR by
overlapping PCR followed by cloning into the XhoI and NotI sites
in PB[Act-RFP].
LSL-PBase plasmid was generated from DNA elements in the
plasmids Act-PBase [3] and pBS302. A 1.5-kb transcriptional
termination sequence flanked by loxP sites was obtained from the
pBS302 plasmid by digestion with EcoRI and SpeI, and
subsequently cloned between the Actin promoter and PBase
coding sequence in the Act-PBase plasmid. Two copies of the
chicken b-globin HS4 core enhancer from the plasmid pNI-CD were
also cloned upstream of the Actin promoter.
PBaseER was generated by inserting a 12-nucleotide linker
sequence that encodes a four-amino acid, positively charged linker
(59-AGGCGCGCCCCC-39) between the PBase coding sequence
and the mutated tamoxifen-responsive mouse estrogen receptor
hormone-binding domain coding sequence [45]. PBaseER was
subsequently cloned after the Actin or LSL promoter.
Figure 5. Tissue-specific PB-SMART. (A) Activation of the conditional
LSL-PBase enables tissue-specific mutagenesis by crossing transgenic mice
to available Cre lines. (B) Luc-PB[mut]7;LSL-PBase;Ksp-Cre transgenics (red
bars) undergo PB mutagenesis specifically in the seminal vesicles and
kidneys, reported by luciferase signal. Control mouse: Luc-PB[mut]7;
LSL-PBase (blue bars). Units, photons?s
21?cm
22?sr
21.( C)P Bm u t a g e n e s i s
throughout the skin of Luc-PB[mut]7;LSL-PBase;K14-Cre mice (red bar) is
reported by luciferase signal. Control mouse: Luc-PB[mut]7;K14-Cre (blue
b a r ) .U n i t s ,p h o t o n s ?s
21?cm
22?sr
21.( D) Tyr-CreER conditionally activates
Braf
V600E and PB mutagenesis specifically in melanocytes of quadruple
transgenic mice (Luc-PB[mut]7;LSL-PBase;Braf
CA;Tyr-CreER,r e db a r s ) .T h e
expansion of this cell population at three, nine, and eleven months (left,
middle and right, respectively) is tracked ex vivo by luciferase signal. Control
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PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e26650Figure 6. Tissue-specific induction of skin phenotypes by Cre-activated PB mutagenesis. (A) Luciferase signal marks clones of mutated
cells in Luc-PB[mut]7;LSL-PBase;K14-Cre mice. (B) PB-induced alopecia in a PB[mut]7;LSL-PBase;K14-Cre; Pten
lox/+ mouse, (yellow dashed line) shows
strong luciferase signal corresponding to hair loss (middle). Fully shaved, luciferase signal demarcates the specific region of alopecia (right).
(C) Cytokeratin staining (green) of wild-type dorsal skin shows the normal thickness of the mouse epidermis (white arrowhead). DAPI (blue) marks cell
nuclei. (D) Staining as in (c) from the region of alopecia reveals substantial thickening of the epidermis (white arrowhead). (E) A transposon insertion
upstream of Myc was mapped to the affected region of skin. (F) Skin-specific mutagenesis in Luc-PB[mut]7;LSL-PBase;K14-Cre mice induces tumor




21.( G) Insertion sites (wide arrows) in Gli2 were mapped in multiple skin tumors. (H) By quantitative PCR, Gli2 transcripts
were upregulated in each skin tumor (BCC1, BCC2, BCC3, and BCC4) compared to WT skin. (I) The skin tumors bear resemblance to human basal cell
carcinoma according to histological analysis, consistent with the activation of the Hedgehog pathway (scale bar, 50 mm).
doi:10.1371/journal.pone.0026650.g006
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Luc-PB[mut] and PB[mut-RFP] plasmids were linearized by NotI
or PspXI. LSL-PBase plasmid was linearized by SalI and StuI. Act-
PBaseER was linearized by SalI and BamHI. After gel purification
(Qiagen), linear DNA was injected into C57BL/6J x SJL/J F2
hybrid one-cell embryos. Founders were screened for the presence
or absence of the transgene by PCR analysis (see Table S1 for
primer sequences).




cre)91Igr/J), and K14-Cre (Tg(KRT14-cre)1Amc/J) lines have been
reported previously [3,20,36,37]. Pten
+/ were generated by mating
a Pten
lox/+ male to a Pbsn-Cre4 (B6.Cg-Tg(Pbsn-cre)4Prb) female to
induce recombination in the germline [46]. Transgenic mice were
backcrossed to the FVB/NJ mouse strain. Animals were fed a
standard rodent diet.
Administration of tamoxifen to mice
100 mg/ml tamoxifen was dissolved in ethanol and diluted 1:10
in sunflower seed oil (for intraperitoneal injection) or 1:100 in
water (for tamoxifen-water bottles). Newly weaned mice were
injected with 100 ml (1 mg) tamoxifen-in-oil mixture once per day
for five consecutive days. For tamoxifen-water bottles, mice were
constantly kept on 100 mg/ml tamoxifen-water.
Histology and immunofluorescence
For paraffin-embedded sections, tissues were dissected from
euthanized mice and fixed in 10% neutral-buffered formalin
overnight, dehydrated in a series of increasing concentrations of
ethanol and xylenes, embedded in paraffin, sectioned, and stained
with hematoxylin and eosin. For frozen sections, dissected tissues
were OCT-embedded, frozen, sectioned, and fixed in 4%
paraformaldehyde (PFA). For immunofluorescence staining of
cytokeratin, OCT sections were fixed for 10 min in 4% PFA in
PBS and washed three times for 5 min in PBS. Sections were
permeabilized with 0.1% Triton for 15 min, washed three times
for 5 min in PBS, and blocked for one hour with blocking solution
(5% NGS, 1% BSA, and 0.1% Triton X-100 in PBS). Rabbit anti-
cow cytokeratin wide spectrum screening antibody (1:250, Dako)
was added overnight at 4uC. Alexa Fluor 488 goat anti-rabbit IgG
(1:2000; Invitrogen) was used for detection of primary antibodies
and nuclei were stained with DAPI. Blocking solution and
antibody incubation steps were performed in a humidified
chamber.
Ex vivo mouse imaging
Mice were sedated using an isoflurane vaporizer. For ex vivo
visualization of RFP, sedated PB[mut-RFP] control and PB[mut-
RFP];Act-PBase mice were shaved and immediately imaged side-
by-side in the IVIS Spectrum (Xenogen) by epifluorescence.
Autofluorescence in shaved regions was quantitated in control
mice to adjust epifluorescence imaging parameters. To visualize in
vivo luciferase activity using the IVIS Spectrum, sedated mice were
weighed, treated with 150 mg luciferin per kg body weight via
intraperitoneal injection, and subsequently imaged 15 minutes
after luciferin injection.. Heart rate and respiration were closely
monitored and body temperature was regulated throughout the
entire procedure.
Linker-mediated PCR identification of PB insertion sites
LM-PCR mapping of PB mutator insertion sites was
performed using a previously developed protocol [47] with the
following modifications. Two mg of mouse genomic DNA were
digested overnight with Sau3AI or MspI and subsequently heat
inactivated. Double-stranded Sau3AI-specific or MspI-specific
linkers were ligated to digested genomic DNA in an overnight
reaction at 18uC. Ligation products were digested in a second
reaction by MfeI to eliminate adaptor-ligated DNA fragments
containing mutator transposon at its original site of insertion.
Following heat inactivation of enzyme and purification of
digestion products (Qiagen), a primary PCR reaction, followed
by a nested PCR reaction, were performed. Amplification
products were purified (Qiagen), TA-cloned into the pGEM-T-
Easy vector (Promega), and transformed in competent cells.
Colonies were screened for inserts by colony PCR using the T7
and SP6 primers and those containing inserts sequenced by
traditional Sanger sequencing. Oligonucleotides used in this
procedure can be found in Table S1.
Sequence analysis and annotation
Insertion sites were mapped by Blatting against the mouse
genome with UCSC Genome Bioinformatics Site (http://genome.
ucsc.edu/).
RNA isolation and quantitative PCR
RNA was isolated from tumors or wild type tissues (Qiagen). 1–
2 mg of RNA was then used with oligo-dT primer and Superscript
III (Invitrogen) to synthesize cDNA. Quantitative PCR with
SYBR green in the StepOne Real-Time PCR instrument (Applied
Biosystems) was used to determine transcript levels with the
relative standard curve method. Primers are detailed in Table S1.
Excision PCR
Quantitative PCR was used to determine the relative excision
levels of Luc-PB[mut] from spleen genomic DNA. Mobilization of
PB[mut-RFP] from the concatamer was determined by traditional
PCR using primers designed against the plasmid sequences
flanking the PB[mut-RFP] transposon. Primer sequences are
detailed in Table S1.
Cell culture
HEK 293 cells were grown in DMEM containing 10% FBS
under standard conditions. Cells were transfected with circular
plasmids using Lipofectamine 2000 according to the manufactur-
er’s instructions (Invitrogen). To select neomycin-resistant colo-
nies, Geneticin (G418) was added to the culture medium at a
concentration of 500 mg/ml. For two weeks, culture medium was
replaced every 3–4 days and G418 was resupplemented each time.
To induce PBaseER activity, 4-hydroxtamoxifen (4-OHT) was
added to culture medium to obtain the desired final concentration.
Confocal microscopy
HEK293 cells were seeded onto sterilized cover slips, cultured
until 90% confluent, and then fixed in 4% paraformaldehyde
(PFA) for 15 minutes at room temperature. Following permeabi-
lization using 0.1% Triton X-100 in PBS (PBST), cells were
blocked with 5% normal goat serum at room temperature for 30
minutes and then incubated with primary antibodies. The ERa
primary antibody (sc-542, Santa Cruz Biotechnology) and mouse
monoclonal anti-myc 9E10 primary antibodies were used. FITC-
conjugated secondary antibodies were used to visualize proteins.
Samples were mounted in Vectashield containing DAPI (Vector
Laboratories). Immunofluorescence images were collected using a
Zeiss LSM Meta confocal microscope and processed using Adobe
Photoshop.
PB-SMART for Genetic Screens in Mice
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To stain colonies in tissue culture dishes, culture medium was
aspirated by vacuum and washed once in PBS. Subsequently, cells
were fixed in ice cold methanol for 20 minutes at room
temperature. Staining was performed using 0.2% methylene blue
solution for one hour at room temperature. Following this step, the
culture dishes were rinsed with distilled water to remove residual
stains.
Western blotting
Cells were lysed in lysis buffer and protein concentrations of
lysates were determined by the BCA Assay (Pierce). Approxi-
mately 15 mg of total protein was loaded on a 10% SDS-PAGE
gel. Protein was transferred onto the Trans-Blot Transfer Medium
(Biorad). Nitrocellulose membranes were blocked at room
temperature for 1 hour with 5% milk in PBS, then washed 3
times for 10 minutes in PBS and incubated with ERa primary
antibody (sc-542, Santa Cruz Biotechnology) in PBS and 3% BSA
overnight at 4uC. Membranes were washed 3 times for 10 minutes
in PBS, blocked at room temperature for 1 hour with 5% milk in
PBS, and incubated in HRP-conjugated secondary antibodies.
Immunoreactive bands were visualized using Western Lightning
Plus-ECL (Perkin-Elmer).
Supporting Information
Figure S1 Tamoxifen-dependent translocationof PBaseER
to the nucleus drives PB transposition in HEK 293 cells. (A)
Act-PBaseER in transfected HEK 293 cells was detected by
Western blotting using a polyclonal ERa antibody and displayed
the expected size. (B) Immunofluorescent staining with ERa
antibody revealed that PBaseER translocates to the nucleus after
24-hour 4-hydroxytamoxifen (4-OHT) treatment. (C) HEK 293
cells co-transfected with circular plasmids carrying PB with a
neomycin resistance cassette (PB[SV40-neo]) and Act-PBase form
G418-resistant clones after drug selection for two weeks, indicative
of PBase-mediated transposition activity. (D) 4-OHT treatment is
required for PBaseER-mediated transposon insertion. Compared
to Act-PBase, Act-PBaseER mediates transposition at a lower
efficiency.
(TIF)
Table S1 Primers used in this work for genotyping transgenic
lines, analyzing PB excision, analyzing PB copy number, analyzing
relative transcript levels, and mapping PB insertion sites.
(DOC)
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